HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF CANCER

Title:

HUMANIZED ANTI-LIV1 ANTIBODIES FOR THE TREATMENT OF CANCER

Document Type and Number:

WIPO Patent Application WO/2022/067348

Kind Code:

A9

Abstract:

Methods for using anti-LIV1 antibodies and antibody-drug conjugates, including anti-LIV1 antibody-drug conjugates, to inhibit proliferation of a cell, as well as for the treatment of cancers, such as, e.g., prostate cancer and melanoma, are provided.

Inventors:

ONSUM MATT (US)
LU HAILING (US)
WANG ZEJING (US)

Application Number:

PCT/US2021/071609

Publication Date:

June 30, 2022

Filing Date:

September 27, 2021

Export Citation:

Click for automatic bibliography generation Help

Assignee:

SEAGEN INC (US)

International Classes:

C07K16/28; A61K39/395; A61K47/68; A61P35/00

Attorney, Agent or Firm:

CHAN, Ngam Fung David et al. (US)

Download PDF:

View/Download PDF PDF Help

Previous Patent: METHODS OF TREATING SOLID TUMORS DRIVEN BY HER2 ALTERATIONS WITH TUCATINIB IN COMBINATION WITH AN AN...

Next Patent: ELECTRICALLY GROUNDING CASSETTE SEAL